HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.

Abstract
During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines. We analyzed human lymph nodes after infection or mRNA vaccination for correlates of serological differences. Antibody breadth against viral variants is lower after infection compared with all vaccines evaluated but improves over several months. Viral variant infection elicits variant-specific antibodies, but prior mRNA vaccination imprints serological responses toward Wuhan-Hu-1 rather than variant antigens. In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks postvaccination in some cases. SARS-CoV-2 antibody specificity, breadth, and maturation are affected by imprinting from exposure history and distinct histological and antigenic contexts in infection compared with vaccination.
AuthorsKatharina Röltgen, Sandra C A Nielsen, Oscar Silva, Sheren F Younes, Maxim Zaslavsky, Cristina Costales, Fan Yang, Oliver F Wirz, Daniel Solis, Ramona A Hoh, Aihui Wang, Prabhu S Arunachalam, Deana Colburg, Shuchun Zhao, Emily Haraguchi, Alexandra S Lee, Mihir M Shah, Monali Manohar, Iris Chang, Fei Gao, Vamsee Mallajosyula, Chunfeng Li, James Liu, Massa J Shoura, Sayantani B Sindher, Ella Parsons, Naranjargal J Dashdorj, Naranbaatar D Dashdorj, Robert Monroe, Geidy E Serrano, Thomas G Beach, R Sharon Chinthrajah, Gregory W Charville, James L Wilbur, Jacob N Wohlstadter, Mark M Davis, Bali Pulendran, Megan L Troxell, George B Sigal, Yasodha Natkunam, Benjamin A Pinsky, Kari C Nadeau, Scott D Boyd
JournalCell (Cell) Vol. 185 Issue 6 Pg. 1025-1040.e14 (03 17 2022) ISSN: 1097-4172 [Electronic] United States
PMID35148837 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antibodies, Viral
  • Antigens, Viral
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • BNT162 Vaccine
Topics
  • Antibodies, Viral
  • Antigens, Viral
  • BNT162 Vaccine
  • COVID-19 (prevention & control)
  • Germinal Center
  • Humans
  • SARS-CoV-2 (genetics)
  • Spike Glycoprotein, Coronavirus
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: